

# **SHARING EVENTS**

Impact of diabetes drugs on cardiovascular and renal disease in type 2 diabetes

La diagnosi di nefropatia diabetica C. Zoccali




Evoluzione della diagnosi di nefropatia diabetica, storia naturale della malattia, l'albuminuria come elemento centrale per strategie preventive

Oltre l'albuminuria, strumenti di «precision nephrology»

## Autopsy study: eight\_patients who died of renal failure


hypertersion, heavy albuminuria, and edema Seven out eight were diabetic



The archetype lesion of diabetic nephropathy

Kimmelstiel P, Wilson C. Intercapillary lesions in glomeruli of kidney. Am J Pathol. 1936;12:83.


## !! Highly specific to diabetes



**Arthur C Allen.** So-called intercapillary glomerulosclerosis—a lesion associated with diabetes. Arch Pathol. 1941;32:33–51.

## Autopsy study: eight patients who died of renal failure

hypertension, heavy albuminuria edema Seven out eight were diabetic




Kimmelstiel P, Wilson C. Intercapillary lesions in glomeruli of kidney. Am J Pathol. 1936;12:83.

#### 1945-1980...a flurry of studies on proteinuria in diabetes...>400 papers in PubMed



Mechanistic and cohort studies of the etiologic and prognostic role of albuminuria in patients with type 1 and 2 diabetes in Denmark in '70-'80



.... incipient diabetic nephropathy (DN) is classically defined by increasing albuminuria, heralding a decline in glomerular filtration rate (GFR)

.... which usually does not occur until the transition to macroalbuminuria (overt DN).

## Porrini et al., Lancet Diabetes Endocrinol 2015; 3: 382-91

# 1988-2014 Community-based surveys of the occurrence of low GFR and albuminuria in type 2 diabetics

		Or it aria arban		of Karia dibarrillaria in type 2 diabeties				
	N	Outcomes	Comments					
		GFR < 60 mL/min per 1.73 m <sup>2</sup>	Albuminuria/proteinuria					
Cross-sectional studies	Higher	risk for progression to	macroalbuminuria in males					
Kramer et al (2003) <sup>17</sup> (NAHNES 1988–1994)	1197	171 (14%)	36% normoalbumir fria 45% microalbumir v. 19% macroalbuminuria or	nacroalbuminuria or afACE inhibitors				
MacIsaac et al (2004)18	301	109 (36%)*	39% normoalbuminuria	puminuria				
19% GFR <	60 ml/	min/.1.73 m <sup>2</sup>	35% microalbuminuria microalbum 26% macroalbuminuria	inuria Normoalbuminuria ACE inhibito				
So et al (2006) <sup>19</sup>	4421	528 (12%)	14% normoalbuminuria 26% microalbuminuria 60% macroalbuminuria or pl	57%				
Yokoyama et al (2009) <sup>20</sup>	3297	506 (15%)	52% normoalbuminuria 21% microalbuminuria 27% macroalbuminuria or proteinuria	oncentrations, smoking retinopathy.				
Thomas et al (2009) <sup>21</sup> (NEPHRON 11)	3892	920 (23%)	55% normoalbuminuria 32% microalbuminuria 13% macroalbuminuria or proteinuria	Female sex a risk fac : 14% retinopathy; use of ACE inhibtors > 80%				
Penno et al (2011) <sup>22</sup> (RIACE study)	15773	2959 (19%)	57% normoalbuminuria 31% microalbuminuria 13% macroalbuminuria or proteinuria	Risk factors: female sex, obesity, triglyceride concentrations, hypertension 32% retinopathy; 43% no retinopathy plus microalbuminuria or proteinuria: use of ACE inhibitors > 70%				
Dwyer et al (2012) <sup>23</sup> (DEMAND study)	11573	2586 (22%)	40% normoalbuminuria 47% microalbuminuria 13% macroalbuminuria or proteinuria	Risk factors: female sex, hypertension, retinopathy, dyslipidaemia, smoking, hyperglycaemia				
Mottl et al (2013) <sup>24</sup> (NA HNES 2001-2008)	2798	575 (21%)	52% normoalbuminuria 48% microproteinuria	Chronic kidney disease, normoalbuminuria and microalbuminuria more frequent in women than in men; hypertension and hyperglycaemia were protective factors				
Boronat et al (2014) <sup>25</sup>		78 (GFR < 30 ml/min)	22% normoalbuminuria 20% microalbuminuria 58% proteinuria	Female sex a risk factor; hyperglycaemia and polyneuropathy were protective factors; 29% retinopathy in normoalbuminuria, 53% in microalbuminuria or proteinuria				

# **UK Prospective Diabetes Study (UKPDS-74)**



14% normoalbuminuric patients developed GFR <60 mL/min/1.73 m<sup>2</sup> as the sole alteration

Follow up 15 years

Diabetes 2006; 55: 1832-39.


# Atherosclerosis in the community (ARIC)



56% who developped GFR <60 mL/min/1.73 m<sup>2</sup> were initially normoalbuminuric

Follow up 11 years


Arch Intern Med 2008; 168: 2440-47.



Diabetic Kidney Disease: evidence of renal dysfunction (i.e. GFR loss) and/or damage (albuminuria) in patients with diabetes

# GFR decline (ml/min/1.73 m²) and albuminuria

data from studies that did repeated golden standard GFRs





**Clino-Pathological relationship** Strong relation with albuminuria in the seminal small series by Kimmelstiel

# **Renal Structure in Normoalbuminuric** and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function

EKINCI IF et al., **Diabetes Care** 36:3620–3626, 2013




Type 2 diabetics CKD stage G3-4


~37% ~83%

~100%

Normo A 0-30mg/g creatinine 30-300 mg/g creatinine

MacroA >300 mg/g creatinine








Evoluzione della diagnosi di nefropatia diabetica, storia naturale della malattia, l'albuminuria come elemento centrale per strategie preventive


Oltre l'albuminuria, strumenti di «precision nephrology»


## Pathway to Diabetic Nephropathy and Kidney failure



Healthy

**KIDNEY** 





failure


**PROTEOMICS** 

μΑ


Structural organ damage



**5010** peptides








**273** peptides ⇒ CKD**273** 

74% collagen fragments. Reduced peaks of most of these these fragments was the most prominent difference between Healthy subjects and CKD patients.

<u>Interpretation</u>: due to reduced degradation (by metalloproteinases) collagen accumulates in the extracellular matrix leading to kidney fibrosis.

# Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Petra Zürbig, George Jerums, Peter Hovind, Richard J. MacIsaac, Harald Mischak, Stine E. Nielsen, Sianna Panagiotopoulos, Frederik Persson, and Peter Rossing



**Diabetes** 61:3304–3313, 2012



316 urine samples Samples were available from patients with type 1 (n = 16) or type 2 (n = 19)

μ-Albuminuria
initially normoalbuminuric
diabetic patients Macro Albuminuria
YES/No
CKD273

# Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Petra Zürbig, George Jerums, Peter Hovind, Richard J. MacIsaac, Harald Mischak, Stine E. Nielsen, Sianna Panagiotopoulos, Frederik Persson, and Peter Rossing

**Diabetes** 61:3304–3313, 2012

## **Prediction Time**

μ-albuminuria


3.4 years earlier


**Macro Albuminuria** 

4.9 years earlier

CKD273 classifier

#### **Correct Prediction of Macroalbuminuria**







#### DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE

Food and Drug Administration Center for Drug Evaluation and Research 10903 New Hampshire Avenue Silver Spring, MD 20993

Date: June 14, 2016

ATTN: Harald Mischak, Dr. Med. Habil, Ph.D.

Mosaiques-diagnostics GmbH

Rotenburger Str. 20 D-30659 Hannover GERMANY

Subject: Biomarker Letter of Support

Dear Dr. Mischak,

We are issuing this Letter of Support to Mosaiques Diagnostics GmbH to encourage the further development of CKD273, a prognostic enrichment biomarker panel composed of 273 urinary peptides, to be used in combination with current measures (i.e., albuminuria, serum creatinine) in early phase clinical trials in diabetic kidney disease (DKD) to identify patients with early stage disease who may be more likely to progress. For a listing of the components of the CKD273 biomarker panel, please see Appendix 1.

Nephrol Dial Transplant (2017) 1–9 doi: 10.1093/ndt/gfx068

1-9, 2017



Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion

#### Elena Critselis<sup>1</sup>, Antonia Vlahou<sup>1</sup>, Vianda S. Stel<sup>2</sup> and Rachael L. Morton<sup>3</sup>

<sup>1</sup>Proteomics Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, <sup>2</sup>ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands and <sup>3</sup>National Health and Medical Research Council Clinical Trials Centre, University of Sydney,

CKD273 use approved in Germany ...already available as an *in vitro* diagnostic device for the early detection of CKD in diabetic patients.

urine sample is shipped overnight to the analytical laboratory, and the results are reported back to the sender within 5 days.

cost still covered by some private health insurance companies only.

# S & C

Diabetic nephropathy is a structurally and pathophysiologically heterogeneous disease and and may evolve into kidney failure both in albuminuric and non-albuminuric patients


the severity of albuminuria goes along with the rate of GFR loss.

In normoalbuminuric patients female gender, hypertension, overweight-obesity, are the main risk factors for the risk of CKD

A new peptidomic classifier outperforms albuminuria for the prediction of Macro-Albuminuria. Initial cost-effectiveness analyses support further development of this classifier.




Mechanistic and cohort studies in patients with type 1 and 2 diabetes in Denmark in '70-'80



Albuminuria remains the most applied biomarker for prevention of Diabetic Nephropathy

Diabetes 1983; 32 (suppl 2): 64-78.




# Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Petra Zürbig, <sup>1</sup> George Jerums, <sup>2</sup> Peter Hovind, <sup>3</sup> Richard J. MacIsaac, <sup>4</sup> Harald Mischak, <sup>1,5</sup> Stine E. Nielsen, <sup>3</sup> Sianna Panagiotopoulos, <sup>2</sup> Frederik Persson, <sup>3</sup> and Peter Rossing <sup>3</sup>

**Diabetes** 61:3304–3313, 2012

### Prognostic value of $\mu$ -albuminuria and CKD273 for Macroalbuminuria



# Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Petra Zürbig, <sup>1</sup> George Jerums, <sup>2</sup> Peter Hovind, <sup>3</sup> Richard J. MacIsaac, <sup>4</sup> Harald Mischak, <sup>1,5</sup> Stine E. Nielsen, <sup>3</sup> Sianna Panagiotopoulos, <sup>2</sup> Frederik Persson, <sup>3</sup> and Peter Rossing <sup>3</sup>

**Diabetes** 61:3304–3313, 2012

### Prognostic value of $\mu$ -albuminuria and CKD273 for Macroalbuminuria





μ-albuminuria

3.4 years earlier
Macro Albuminuria

4.9 years earlier

CKD273 classifier





Several RCT testing RAS inhibitors and other therapies

#### **Diabetic Kidney Disease**

.... incipient diabetic nephropathy (DN) is classically defined by increasing albuminuria, heralding a decline in glomerular filtration rate (GFR) .... which usually does not occur until the transition to macroalbuminuria (overt DN).

However, a high proportion of patients with either type 1 or type 2 diabetes does not follow this classical albuminuric pathway, instead showing declining renal function in the absence of an elevated albumin excretion rate

Diabetic Kidney Disease: evidence of renal dysfunction (i.e. GFR loss) or damage (albuminuria) in patients with diabetes

## **Renal Pathology Society classification**

Class I Isolated glomerular basement membrane thickening

Class II Mild (class IIa) or severe (class IIb) mesangial expansion

Class III At least one Kimmelstiel-Wilson lesion (nodular intercapillary glomerulosclerosis) is observed on biopsy and there is <50 percent global glomerulosclerosis

Class IV There is >50 percent global glomerulosclerosis that attributable to diabetic nephropathy

Tervaert TW et al. J Am Soc Nephrol. 2010;21(4):556.